Related Experiment Video
Updated: Jan 31, 2026
06:18
A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
Published on: March 3, 2023
1.8K
Drug-eluting stents and vulnerable plaque
Mehmet Cilingiroglu1, Faisal Khan
1University of Cincinnati Medical Center, 231 Albert Sabin Way, Cincinnati, OH 45267, USA. mcilingiroglu@yahoo.com
Current Atherosclerosis Reports
|February 21, 2009
Summary
Early intervention with drug-eluting stents may prevent acute coronary syndromes (ACS) caused by vulnerable plaque in mildly obstructive coronary lesions. This approach could reduce mortality from this leading cause of death.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Biology
Background:
- Acute coronary syndromes (ACS) are the leading global cause of mortality.
- ACS often result from vulnerable plaque rupture and thrombus formation in coronary arteries.
- Vulnerable plaques are frequently found in mildly obstructive lesions (<50% stenosis).
Purpose of the Study:
- To review the potential for early treatment of mildly obstructive coronary lesions.
- To evaluate the use of drug-eluting stents (DES) for preventing ACS.
- To assess the long-term efficacy of DES in managing these lesions.
Main Methods:
- Review of existing data on ACS, vulnerable plaque, and coronary lesion severity.
- Analysis of studies involving patients with ACS and prior coronary angiograms.
- Evaluation of the impact of percutaneous coronary interventions (PCI) and DES on restenosis and long-term outcomes.
Main Results:
- Vulnerable plaques leading to ACS are often associated with moderate, not severe, coronary stenosis.
- Percutaneous coronary intervention (PCI) for mildly obstructive lesions faces restenosis challenges.
- Drug-eluting stents (DES) have significantly reduced in-stent restenosis, improving long-term outcomes.
Conclusions:
- Early treatment of mildly obstructive coronary lesions with DES may prevent ACS.
- DES offer improved long-term efficacy compared to traditional PCI for these lesions.
- Further data is needed to confirm the preventative role of early DES intervention in ACS.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
268
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
268
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
158
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
158
01:25Pharmacokinetics: Drug–Drug Interactions
440
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
440
01:05High-Performance Liquid Chromatography: Elution Process
1.5K
In High-Performance Liquid Chromatography (HPLC), the elution process is critical to the separation of analytes and the quality of chromatographic results. Elution describes how compounds move through the column and separate based on their interactions with the mobile and stationary phases. This process determines the resolution, peak shape, and retention times in the chromatogram, which are essential for identifying and quantifying components in complex mixtures. Understanding the elution...
1.5K
01:27Factors Influencing Drug Absorption: Drug Dissolution
1.2K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.2K
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
484
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
484